GlassScriptPhysician profile
Mohammed S Khan
NPI 1932170149
$11,615.79
in general payments reported to CMS, 2019-2025
41 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $676 · 2021: $455 · 2022: $2,317 · 2023: $3,779 · 2024: $1,501 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,710 · Travel and Lodging: $2,095 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,710.21 |
| Travel and Lodging | $2,094.72 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,889.05 | 2019-2024 | Xience Xpedition, Xience Skypoint, Aveir |
| Alphatec Spine, INC | $1,820.80 | 2019-2022 | |
| Amgen INC. | $526.26 | 2019-2025 | Repatha, Repatha |
| Abiomed | $414.49 | 2019-2024 | Impella |
| Merck Sharp & Dohme LLC | $375.43 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $345.22 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $339.11 | 2023-2025 | Watchman Flx, Bodyguardian |
| Biotronik INC. | $319.62 | 2019-2021 | |
| Cvrx, INC. | $276.71 | 2025 | Barostim Neo System |
| Cordis US Corp. | $261.78 | 2025 | Selution Slr Ptca |
| Novo Nordisk INC | $253.15 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $227.39 | 2019-2025 | Farxiga |
| Tactile Systems Technology INC | $221.19 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Bard Peripheral Vascular, INC. | $208.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $200.95 | 2019-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $182.14 | 2025 | |
| Pfizer INC. | $179.48 | 2022-2025 | |
| W. L. Gore & Associates, INC. | $142.09 | 2024 | Gore Cardioform Septal Occluder |
| Cardiva Medical, INC. | $133.44 | 2022 | |
| Depuy Synthes Sales INC. | $125.09 | 2021-2024 | Teligen |
| E.R. Squibb & Sons, L.L.C. | $120.19 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $116.14 | 2022-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $112.92 | 2023-2024 | Inpefa |
| Philips North America LLC | $103.85 | 2024 | (Bq9) Coronary Ivus |
| Medtronic, INC. | $100.45 | 2021-2023 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.40 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $81.87 | 2025 | |
| Amarin Pharma, INC. | $63.05 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.32 | 2019-2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $45.57 | 2020-2021 | |
| Astellas Pharma US INC | $41.17 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $33.78 | 2022-2023 | Arcalyst |
| Cleerly, INC. | $30.31 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Sanofi-Aventis U.S. LLC | $30.06 | 2022 | |
| Ethicon US, LLC | $28.11 | 2024 | Ethicon |
| Kiniksa Pharmaceuticals International, Plc | $24.58 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $22.06 | 2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2025 | |
| Teleflex LLC | $16.19 | 2023 | Supercross |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2019 | |
| Vifor Pharma, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.